Q&A with Rene Anand of Neurxstem Inc.
CEO & Founder
Neurxstem Inc. is a US-based, predictive and precision genomic medicine company
dedicated to finding innovative solutions to the most challenging human brain diseases.
Neurxstem has patented a novel, first-in-class Neural Organoid Platform that closely mimics the human central nervous system. This produces a patented drug discovery technology that is based on brain organoids derived from human stem cells. This technology is unique in that it allows us to study the brain genome in a way that was previously impossible, providing a huge step forward in our understanding of debilitating diseases such as Alzheimer’s, brain cancer, Autism, and Parkinson’s.
Top Innovator Pitch at a SilVal event, May10th-11th, “EmergingTechVentures” – a very big VC only event in CA.
Top Innovator Pitch at ‘TechConnectWorld’ event in DC June 19th-21st. This one is a VC pitch and the second 20-minute science presentation on precision health symposium at the same event.
Top Innovator Pitch at 2023 BioPartnering Conference, April 18th.
Sponsored by JP Morgan, J&J Innovation, and Morgan Lewis
Big Pharma looking for drugs for cures.
Neurxstem selected as an Innovator Showcase Presenter at the ADDF Aging symposium on April 13th, in Berkeley!
Pitch Presentations from 10 Selected Companies: Introduction
View the Family Office Insights Luminary Series Interview featuring Dr. Rene Anand, entrepreneur, and CEO & Founder of Neurxstem, Inc., an Avant-garde precision and predictive genomic brain medicine company developing early diagnostics and therapeutics for debilitating brain disease and disorders, including Alzheimer’s, Parkinson’s, autism, PTSD, Pain, and Brain Cancer and Aging (progeria).
Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com
What makes human brain models so important for finding cures for brain diseases and diorders?
Mouse models, the standard 'status quo' for decades have been very misleading and caused repeated failure of big Pharma to bring to market effective cures. The financial loss has been for investors and the government >$100B
How do you know your stem cell brain models for Alzheimer's disease is correctly reflecting AD etiology?
We know this because the hundreds of genes dysregulated in our AD models compared to those from normal donor models match those of both AD patient postmortem brains as well as those of recent genetic studies from AD patients.
Do you have promising drugs for Alzheimer's that dont target the gravestone markers of AD - amyloid plaques and tau fibrils? If so how do you know they are 'promising' in pre-clinical testing with the AD models as part of your journey to IND enabling studies for FDA approval and clinical trials? Are any of them already FDA approved and repurposed drugs, that can be brought to market rapidly after a Phase 2 trial?
We have used the big data from our models to do data analytics to find the likely early causes of AD and once we found them, we then tested drugs against them. They are 'promosing' because they reverse the changes in gene expression of differences between AD and normal brain models. The reversal is for hundreds of upstream genes and early genes that re drivers of AD pathology and eventually cognitive failure as we age.
Rene Anand of Neurxstem Inc.
Contact Rene: firstname.lastname@example.org